Kurt Gielen – VJRegenMed

Challenges in manufacturing advanced therapies for researchers

Simon Ng — Fri, 21 Jan 2022 11:14:50 +0000

Kurt Gielen, MedAce, Maastricht, The Netherlands, discusses issues researchers and academics may face when commercializing their therapies for clinical use. Researchers may not have the relevant experience in manufacturing products, and due to the novel nature of the treatments, regulatory authorities may have difficulties in assessing them based on existing guidelines. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Ensuring successful commercialization of advanced therapies

Simon Ng — Fri, 21 Jan 2022 11:14:48 +0000

Kurt Gielen, MedAce, Maastricht, The Netherlands, comments on important factors researchers and academics must consider when attempting to commercialize their product for clinical use. He highlights the need to focus on developing the final product, as opposed to constantly making changes. The financial aspects of developing the product must also be considered, as long term costs such as manufacturing costs will overshadow the viability of the product regardless of scientific innovations. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Supporting start-ups to accelerate biomedical innovations

Simon Ng — Tue, 11 Jan 2022 17:26:16 +0000

Multiple start-ups face issues relating to clinical translation of their products due to development process. Kurt Gielen, MedAce, Maastricht, The Netherlands, describes how MedAce collaborates with companies to help them prepare their products for clinical use by providing research and development facilities, as well as regulatory consulting which many smaller companies face. This interview took place at 6th world congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).